Fourth Annual Future Healthcare Investment Partners Summit 2023: Navigating a Transformative Landscape Amid Global Shifts

In recent years, driven by the dual forces of deepening industry understanding and strengthening investment practices, limited partners (LPs) have become increasingly active in direct investments. Top-tier general partners (GPs) are going all out on both fundraising and investment fronts, with news of oversubscribed funds and lead investments frequently making headlines. Meanwhile, small and mid-sized GPs face ever-shrinking room for survival and development; for them, choosing between a “large and comprehensive” versus a “small and specialized” growth path is far less urgent than the immediate dilemma of “elimination versus survival.” China’s primary equity investment market is gradually forming its own distinct rules of survival.

Looking back at 2022, there were a total of 3,057 financing events in global healthcare investment, with the total amount reaching $72.9 billion (approximately RMB 502.9 billion), lower than in 2020 and 2021, ranking third historically, with an overall trend toward calmness and prudence. Meanwhile, the domestic medical venture capital sector also appeared somewhat subdued in 2022. Data shows that compared to the "first down, then up" trajectory of 2021, financing for medical innovation projects in China's primary market started low and continued to decline throughout the year, shrinking by more than one-third in both the number of events and cumulative amounts. In 2022, the capital landscape of medical investment was markedly different, with a subtle shift in the underlying logic of investment.

The past year presented enterprises and investment institutions with unprecedentedly severe challenges and complex circumstances. As 2023 began, economic activity accelerated its return to normalcy, with all sectors of society prioritizing the stabilization of economic growth as their foremost task. Through concerted efforts, heightened self-imposed pressure, and a race against time, 2023 emerged as a year full of promise. The 4th Future Healthcare Fund Partners Summit, held in 2023, explored value creation and value investment in the global healthcare industry’s capital markets from three perspectives: industrial transformation, changes in China, and global shifts.

Industry Shift: Where Is the Next Battle in Biotechnology?

The healthcare industry has long been a focal point for governments and the public worldwide. With an aging population and the rising prevalence of chronic diseases, the sector faces unprecedented challenges. However, in an era of continuous technological advancement, accelerated exploration in biotechnology has yielded numerous noteworthy disruptive achievements and innovative applications, presenting new opportunities for the healthcare industry.

The healthcare industry is undergoing new changes, global healthcare investment has taken on a new landscape, and every financial event carries fresh insights. Which biotechnology investment opportunities or technological trends are currently capturing capital’s attention? From an investor’s perspective, what kind of biotech companies are needed in this new era? Having just emerged from the industry’s darkest hour, where will the next battleground for biotechnology lie as we look to the future?

China’s Transformation: Consumer Healthcare—The Revolution from Medical Care to Health

As China’s economy grows and living standards improve, people are placing greater emphasis on prevention and wellness rather than merely treatment. Consumer healthcare has become an increasingly prominent topic of public interest.

Consumer healthcare refers to the practice where individuals or families voluntarily select medical services and bear the corresponding costs. At its core, it aims to provide personalized medical services that enable people to better maintain their health and quality of life. In China, consumer healthcare is gradually becoming more diversified and personalized, holding immense market potential. Within the segmented tracks of consumer healthcare, beyond traditional fields such as ophthalmology, dentistry, and medical aesthetics, which other sectors deserve our attention? Currently, China’s consumer healthcare market is shifting toward a health-centric model. This trend is reflected in consumer behavior, with individuals increasingly willing to choose services related to health management and disease prevention. Emerging needs are driving new technologies, which in turn create new consumption scenarios. Where lie the new opportunities for innovation and development in consumer healthcare? How can consumer healthcare companies address customer acquisition challenges and formulate effective solutions? Amidst China’s profound transformation from treatment to prevention and from purely medical care to consumer-oriented services, how can stakeholders seize new opportunities and chart a path for future breakthroughs?

Global Shifts: New Changes and Trends in the Global Biopharmaceutical Ecosystem

The accelerating pace of globalization is driving unprecedented transformation in the biopharmaceutical industry. Factors such as shifts in the regulatory and policy landscape, changes in funding availability and investment directions, evolving innovation trends and technological trajectories, and transformations in innovative talent are all reshaping the global biopharmaceutical ecosystem. Amidst these myriad changes, which developments warrant our attention?

As the world’s two largest economies and among the most advanced nations in the biopharmaceutical industry, China and the United States have followed markedly different development paths and exhibit distinct characteristics. What are the differences and evolving trends between the two countries’ biopharmaceutical sectors? How have these differences and shifts given rise to new dynamics in biopharmaceutical investment in China? With substantial investments in basic research and the integration of technologies such as artificial intelligence and big data, China’s commitment and innovative capacity in biopharmaceuticals continue to grow, gradually establishing it as a key participant and contributor on the global stage. What impact will China’s distinctive model of biopharmaceutical innovation have on global innovation? As the global biopharmaceutical landscape undergoes a renaissance amid these divergences, how can stakeholders identify the associated opportunities and pitfalls?

All of the above will be discussed in depth at the 4th Future Healthcare & Health Fund Partners Summit.

2023 Future Healthcare Top 100 Conference, co-hosted by VB100, VCBeat, and VCBeat Research Institute, with strategic partnership support from Shanghai Zhangjiang Group, will be grandly held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. Led by Academician Robert Langer and IEEE scientists, nearly 500 industry luminaries will gather for three main forums and 31 trending thematic sessions!